## Colon Cancer Screening Rates Lag Despite High Incidence: new Technologies Offer Hope
According to the results of this year’s ‘Cancer Screening Scholarship Survey’ at the National Cancer Center,the rate of colon cancer in 2023 is 70.7%. However, the inspection rate of national health insurance statistics is 41.6% in the same year, the lowest among the six cancers. Because of this very reason, experts cite ‘fecal blood tests’. There are manny inspectors who are reluctant to collect feces directly and submit them to a health check-up agency.
There has been a need to complement a feces blood test that is uncomfortable in the medical and biotechnology industry and is inconvenient and not accurate. in some european countries and the United States, services that filter out the possibility of colorectal cancer have already been commercialized.
### Only 1.3% of colon cancer decisions during feces testing
41.6% of the national health insurance statistics means that only 660,515 out of 1,585,515 national colon cancer screening projects were screened. In the national colorectal cancer screening, those over 50 years of age or older are feced, and when the blood is detected in feces, colonoscopy is performed. The fecal test is ‘basic’.
Conversely, the detection rate of colon cancer thru fecal occult blood tests is very low, only 1.3%. This means that even if a fecal test is performed, the possibility of detecting colon cancer is extremely low.
New Blood Test Shows Promise for Early Colorectal Cancer Detection, Sparks Debate on Screening methods
Table of Contents
A new blood test developed by US-based Singlera Genomics is demonstrating high accuracy in detecting potential colorectal cancer, prompting discussions about its potential to supplement or even reshape current screening practices. The test analyzes circulating tumor DNA (ctDNA) fragments in a simple 8ml blood sample, offering a less invasive option to traditional colonoscopies. With a sensitivity of 86.1% (correctly identifying those with cancer) and a specificity of 91.6% (correctly identifying those without cancer), the test presents a compelling option for early detection.
The Current Landscape of Colorectal Cancer Screening
Colorectal cancer is a leading cause of cancer-related deaths worldwide, but it is indeed highly treatable when detected early. Current screening methods primarily rely on colonoscopies, which, while effective, can be costly, time-consuming, and carry inherent risks.
According to the American Cancer Society, recommended screening options include:
* Colonoscopy: Considered the gold standard, involving a visual examination of the entire colon.
* Fecal Immunochemical Test (FIT): detects hidden blood in stool.
* Stool DNA Test: (e.g., Cologuard) Analyzes stool for cancer cells and altered DNA.
* Flexible Sigmoidoscopy: Examines only the lower portion of the colon.
* CT Colonography (Virtual Colonoscopy): Uses X-rays to create images of the colon.
Singlera genomics’ Blood Test: A Potential “Third Way”
The Singlera Genomics test, which is not yet approved by the FDA, is being positioned as a potential “third test method” to address the limitations of existing screening options.Lim Jae-sung, CEO of Epinode, the company preparing to commercialize the technology in Korea, believes the blood test could increase colorectal cancer detection rates, promote earlier treatment, and ultimately reduce healthcare costs. Hankook ilbo reported on this potential impact.
How it effectively works: The test focuses on identifying minute traces of tumor DNA circulating in the bloodstream. This ctDNA is released by cancer cells and can be detected even before symptoms appear. the high specificity of the test is especially noteworthy, as it minimizes the chance of false positives, which can lead to unneeded follow-up procedures.
Regulatory Status and Future Outlook
Currently, the Singlera Genomics test is not available for routine clinical use in the United States or Korea pending FDA approval.The company is actively pursuing regulatory clearance, and the timeline for approval remains uncertain.
The FDA approval process for ctDNA-based cancer detection tests is rigorous, requiring extensive clinical trials to demonstrate safety and efficacy.The National Cancer Institute provides detailed information on liquid biopsies, including ctDNA analysis, and the challenges associated with their implementation.
Key Takeaways
* A new blood test from Singlera Genomics shows promising results for early colorectal cancer detection.
* The test boasts high sensitivity (86.1%) and specificity (91.6%).
* it offers a less invasive alternative to colonoscopies.
* The test is currently awaiting FDA approval and is not yet widely available.
* The introduction of such tests could considerably impact colorectal cancer screening strategies and healthcare costs.
Frequently Asked Questions (FAQ)
Q: Is this blood test a replacement for colonoscopies?
A: Not necessarily. While the blood test offers a convenient and less invasive option,it may not be a complete replacement for colonoscopies,particularly for individuals at high risk. Further research is needed to determine the optimal role of the test in a extensive screening strategy.
Q: How accurate are current colorectal cancer screening methods?
A: Accuracy varies depending on the method used.Colonoscopies are generally considered the most accurate,but they also carry the highest risk.FIT and stool DNA tests are less invasive but may have lower sensitivity.
Q: What are the next steps for the Singlera Genomics test?
A: The company is focused on obtaining FDA approval and expanding clinical validation studies. They are also working to establish partnerships for commercialization and distribution.
Disclaimer: I am an AI chatbot and cannot provide medical advice. This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is indeed essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.